Integrated pharmacokinetics/pharmacodynamics parameters-based dosing guidelines of enrofloxacin in grass carp Ctenopharyngodon idella to minimize selection of drug resistance

BMC Veterinary Research

Liqun Lu¹  Xianle Yang¹  Hao Wang¹  Lijuan Xu¹ 

[1] Key Laboratory of Freshwater Fishery Germplasm Resources, Ministry of Agriculture, Shanghai Ocean University, Shanghai 201306, People's Republic of China

关键词: Aeromonas hydrophila;    Pharmacodynamics;    Pharmacokinetics;    Grass carp ctenopharyngodon idella;    Enrofloxacin;   

Others  :  1119512
DOI  :  10.1186/1746-6148-9-126

 received in 2013-01-18, accepted in 2013-06-19,  发布年份 2013

【 摘 要 】

Background

Antibiotic resistance has become a serious global problem and is steadily increasing worldwide in almost every bacterial species treated with antibiotics. In aquaculture, the therapeutic options for the treatment of A. hydrophila infection were only limited to several antibiotics, which contributed for the fast-speed emergence of drug tolerance. Accordingly, the aim of this study was to establish a medication regimen to prevent drug resistant bacteria. To determine a rational therapeutic guideline, integrated pharmacodynamics and pharmacokinetics parameters were based to predict dose and dosage interval of enrofloxacin in grass carp Ctenopharyngodon idella infected by a field-isolated A. hydrophila strain.

Results

The pathogenic A. hydrophila strain (AH10) in grass carp was identified and found to be sensitive to enrofloxacin. The mutant selection window (MSW) of enrofloxacin on isolate AH10 was determined to be 0.5 - 3 μg/mL based on the mutant prevention concentration (MPC) and minimum inhibitory concentration (MIC) value. By using high-performance liquid chromatography (HPLC) system, the Pharmacokinetic (PK) parameters of enrofloxacin and its metabolite ciprofloxacin in grass carp were monitored after a single oral gavage of 10, 20, 30 μg enrofloxacin per g body weight. Dosing of 30 μg/g resulted in serum maximum concentration (C_max) of 7.151 μg/mL, and concentration in serum was above MPC till 24 h post the single dose. Once-daily dosing of 30 μg/g was determined to be the rational choice for controlling AH10 infection and preventing mutant selection in grass carp. Data of mean residue time (MRT) and body clearance (CLz) indicated that both enrofloxacin and its metabolite ciprofloxacin present similar eliminating rate and pattern in serum, muscle and liver. A withdraw time of more than 32 d was suggested based on the drug eliminating rate and pharmacokinetic model described by a polyexponential equation.

Conclusions

Based on integrated PK/PD parameters (AUC/MIC, Cmax/MIC, and T>MPC), the results of this study established a principle, for the first time, on drawing accurate dosing guideline for pharmacotherapy against A. hydrophila strain (AH10) for prevention of drug-resistant mutants. Our approach in combining PK data with PD parameters (including MPC and MSW) was the new effort in aquaculture to face the challenge of drug resistance by drawing a specific dosage guideline of antibiotics.

【 授权许可】

   
2013 Xu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Brown SA: Fluoroquinolones in animal health. J Vet Pharmacol Ther 1996, 19:1-14.
• [2]McKinnon PS, Davis SL: Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases. Eur J Clin Microbiol 2004, 23:271-288.
• [3]Fang W, Zhou S, Yu H, Hu L, Zhou K, Liang S: Pharmacokinetics and tissue distribution of enrofloxacin and its metabolite ciprofloxacin in Scylla serrata following oral gavage at two salinities. Aquaculture 2007, 272:180-187.
• [4]Plumb JA, Sheifinger CC, Shryock TR, Goldsby T: Susceptibility of Six bacterial pathogens of channel catfish to Six antibiotics. J Aquat Anim Health 1995, 7:211-217.
• [5]Liu F, Li J, Fu J, Shen Y, Xu X: Two novel homologs of simple C-type lectin in grass carp (Ctenopharyngodon idellus): potential role in immune response to bacteria. Fish Shellfish Immunol 2011, 31:765-773.
• [6]Li X, Wu H, Zhang M, Liang S, Xiao J, Wang Q, Liu Q, Zhang Y: Secreted glyceraldehyde-3-phosphate dehydrogenase as a broad spectrum vaccine candidate against microbial infection in aquaculture. Lett Appl Microbiol 2012, 54:1-9.
• [7]Zhang D, Li A, Xie J, Ji C: In vitro antibacterial effect of berberine hydrochloride and enrofloxacin to fish pathogenic bacteria. Aquac Res 2010, 41:1095-1100.
• [8]Olofsson SK, Cars O: Optimizing drug exposure to minimize selection of antibiotic resistance. Clin Infect Dis 2007, 45(Suppl 2):129-136.
• [9]Alderman DJ, Hastings TS: Antibiotic use in aquaculture: development of antibiotic resistance – potential for consumer health risks. Int J Food Sci Tech 1998, 33:139-155.
• [10]Alcaide E, Blasco MD, Esteve C: Mechanisms of quinolone resistance in Aeromonas species isolated from humans, water and eels. Res Microbiol 2010, 161:40-45.
• [11]Turnidge J: Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 1999, 58(Suppl 2):29-36.
• [12]Caron WP, Mousa SA: Prevention strategies for antimicrobial resistance: a systematic review of the literature. Infect Drug Resist 2010, 3:25-33.
• [13]Liu KY, Wang KY: Study and practice on enrofloxacin in fishery. Chinese J Vet Drug 2004, 38(suppl 10):32-34.
• [14]Roxana B-H, Anabel A, Noemi B, Jesus LR, Maria JF: Comparison of phenotypical and genetic identification of Aeromonas strains isolated from diseased fish. System Appl Microbiol 2010, 3(suppl 33):149-153.
• [15]Giraud E, Baucheron S, Cloeckaert A: Resistance to fluoroquinolones in Salmonella: emerging mechanisms and resistance prevention strategies. Microbes Infect 2006, 8:1937-1944.
• [16]Mckellar QA, Sanchez BSF, Jones DG: Pharmacokinetic/pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine. J Vet Pharmacol Ther 2004, 27:503-514.
• [17]Carbone M, Pennisi MG, Masucci M, Sarro AD, Giannone M, Fera MT: Activity and postantibioticeffect of marbofloxacin, enrofloxacin, difloxacin and ciprofloxacin against feline Bordetella bronchiseptica isolates. Vet Microbiol 2001, 81:79-84.
• [18]Plakas SM, Said KRE, Musser SM: Pharmacokinetics, tissue distribution, and metabolism of flumequine in channel catfish (Ictalurus punctatus). Aquaculture 2000, 187:1-14.
• [19]Samuelsen OB: Pharmacokinetics of quinolones in fish: a review. Aquaculture 2006, 255:55-75.
• [20]Elisa R, Lorena L, Davide G, Pettra C, Giovanni O, Vincenzo DL, Clara M: Approved medication of water with enrofloxacin to treat turkey colibacillosis: Assessment of efficacy using a PK/PD approach. Vet Microbiol 2012, 161:206-212.
• [21]Aneliya H, Valentina U, Mihni L, Vladimir P, Lubomir L: Pharmacikinetic- pharmacodynamic indices of enrofloxacin in Escherichia coli O78/H12 infected chickens. Food Chem Toxic 2011, 49:1530-1536.
• [22]Parra-Sanchez A, Lugo J, Boothe DM, Gaughan EM, Hanson RR, Duran S, Belknap JK: Pharmacokinetics and pharmacodynamics of enrofloxacin and a low dose of amikacin administered via regional intravenous limb perfusion in standing horses. Am J Vet Res 2006, 67:1687-1695.
• [23]Martin BS, Cornejo J, Lapierre L, Iragüen D, Pérez F, Hidalgo H, Andre F: Withdrawal time of four pharmaceutical formulations of enrofloxacin in poultry according to different maximum residues limits. J Vet Pharmacol Ther 2010, 33:246-251.
• [24]Tang J, Yang X, Zheng Z, Yu W, Hu K, Yu H: Pharmacokinetics and the active metabolite of enrofloxacin in Chinese mitten-handed crab (Eriocheir sinensis). Aquaculture 2006, 260:69-76.
• [25]Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Disk and Dilution Susceptibility Test for Bacteria Isolated from Animals; Approved Standard-Third Edition M31-A3. Wayne, PA, USA: CLSI; 2008.
• [26]Su ZX, Xiao H, Chen LH: In vitro antibacterial effect of Chinese herbal medicine against Aeromomonas hydrophila. InformaTech Agric Engineer 2012, 134:233-239.
• [27]Frederique P, Gerardo M: Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella typhimurium and Pseudomonas aeruginosa. Vet Microbiol 2007, 119:304-310.
• [28]Gudmundsson S, Vogelman B, Craig WA: The in-vivo postantibiotic effect of imipenem and other new antimicrobials. J Antimicrob Chemother 1986, 18(Suppl E):67-73.